Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Subscribe To Our Newsletter & Stay Updated
